--- title: "GoodRx vs. Hims & Hers Health: Stagnation vs. Growth in Revenue" type: "News" locale: "en" url: "https://longbridge.com/en/news/285842069.md" description: "Hims & Hers Health outperforms GoodRx in revenue growth, showing consistent upward momentum, while GoodRx's revenue remains flat. GoodRx reported a 4.4% year-over-year decline in Q1 2026, despite a 27% contribution from its Pharma Direct business. Hims & Hers Health, with a 59% year-over-year revenue surge and 13% subscriber growth, is set to announce its Q1 results on May 11, 2026. Investors should monitor the widening revenue gap between the two companies in upcoming quarters." datetime: "2026-05-10T12:55:24.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285842069.md) - [en](https://longbridge.com/en/news/285842069.md) - [zh-HK](https://longbridge.com/zh-HK/news/285842069.md) --- # GoodRx vs. Hims & Hers Health: Stagnation vs. Growth in Revenue ## Key Points - Hims & Hers Health currently leads the revenue comparison against GoodRx, displaying continuous upward momentum across recent reporting periods. - GoodRx has experienced a relatively flat quarter-over-quarter revenue pattern throughout the observed period, whereas Hims & Hers Health has shown consistent, sequential growth. - Investors should watch whether the widening revenue gap between the two companies continues to expand or begins to stabilize in upcoming quarters. - 10 stocks we like better than GoodRx › ## GoodRx: Flat Revenue Trends **GoodRx** (NASDAQ:GDRX) primarily generates revenue by offering a price comparison tool that helps consumers find geographically relevant pricing and access negotiated discounts on prescription drugs across the United States. While expanding its offerings to include new weight-loss medications and navigating a rejected privacy settlement in federal court, it reported about 21% EBIT margin for the quarter ended Dec. 31, 2025. ## Hims & Hers Health: Sequential Revenue Growth **Hims & Hers Health** (NYSE:HIMS) earns its revenue by operating a telehealth network that connects consumers to licensed healthcare professionals, providing medical consultations and ongoing prescription medication subscriptions directly to customers. It shifted its strategy to collaborate with a major pharmaceutical manufacturer and faced several shareholder investigations, while generating approximately 72% gross margin for the quarter ended Dec. 31, 2025. ## Why Revenue Matters for Retail Investors Revenue here refers to the data provider's standardized income-statement revenue line item, and it serves as a straightforward indicator of overall consumer demand that helps investors evaluate whether a business is successfully attracting and retaining users. ## Quarterly Revenue for GoodRx and Hims & Hers Health Quarter (Period End) GoodRx Revenue Hims & Hers Health Revenue Q1 2024 (March 2024) $197.9 million $278.2 million Q2 2024 (June 2024) $200.6 million $315.6 million Q3 2024 (Sept. 2024) $195.3 million $401.6 million Q4 2024 (Dec. 2024) $198.6 million $481.1 million Q1 2025 (March 2025) $203.0 million $586.0 million Q2 2025 (June 2025) $203.1 million $544.8 million Q3 2025 (Sept. 2025) $196.0 million $599.0 million Q4 2025 (Dec. 2025) $194.8 million $617.8 million _Data source: Company filings._ ## Foolish Take The top-line stagnation that has been frustrating GoodRX investors did not improve during the first three months of 2026. On May 6, the medication savings platform reported first-quarter sales that declined by 4.4% year over year to $194 million. Revenue dropped, but GoodRx’s pharma direct business is encouraging investors. The stock rose more than 10% following its first-quarter report. Shareholders seem pleased with an 82% year-to-year gain for the company’s Pharma Direct business. At $52 million, the Pharma Direct business is responsible for about 27% of total revenue. With the average annual cost for a family health plan reaching $27,000 in 2026, fewer Americans have access to a primary care physician. The rising cost of traditional access to prescription drugs has been a strong tailwind for Hims & Hers Health’s alternative platform. His & Hers will announce first-quarter results on May 11, 2026. In the fourth quarter of 2025, the company reported 13% year over year subscriber growth. With fourth-quarter revenue that surged 59% year over year, it’s clearly outperforming GoodRx. ## Should you buy stock in GoodRx right now? Before you buy stock in GoodRx, consider this: The _Motley Fool Stock Advisor_ analyst team just identified what they believe are the **10 best stocks** for investors to buy now… and GoodRx wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when **Netflix** made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, **you’d have $471,827**!\* Or when **Nvidia** made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, **you’d have $1,319,291**!\* Now, it’s worth noting _Stock Advisor’s_ total average return is 986% — a market-crushing outperformance compared to 207% for the S&P 500. **Don't miss the latest top 10 list, available with _Stock Advisor_, and join an investing community built by individual investors for individual investors.** See the 10 stocks » _\*Stock Advisor returns as of May 10, 2026._ _Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends GoodRx. The Motley Fool has a disclosure policy._ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ### Related Stocks - [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md) - [GDRX.US](https://longbridge.com/en/quote/GDRX.US.md) - [IHF.US](https://longbridge.com/en/quote/IHF.US.md) - [HIMY.US](https://longbridge.com/en/quote/HIMY.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [HIMZ.US](https://longbridge.com/en/quote/HIMZ.US.md) - [XHS.US](https://longbridge.com/en/quote/XHS.US.md) - [NFLX.US](https://longbridge.com/en/quote/NFLX.US.md) - [NVDA.US](https://longbridge.com/en/quote/NVDA.US.md) - [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md) - [NVD.DE](https://longbridge.com/en/quote/NVD.DE.md) ## Related News & Research - [Why Hims & Hers Health stock just crashed](https://longbridge.com/en/news/286133577.md) - [Hims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product 'Noise': Analysts](https://longbridge.com/en/news/286130715.md) - [BUZZ-Hims & Hers Health shares stabilize after boosted $350 mln convertible deal](https://longbridge.com/en/news/286896810.md) - [Should you buy the dip in Peloton stock?](https://longbridge.com/en/news/286656768.md) - [Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?](https://longbridge.com/en/news/286135059.md)